Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Para-n-benzene - sulfoxy-n containing doai – and said benzene...
Patent
1996-06-28
1998-12-15
Ketter, James
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Para-n-benzene - sulfoxy-n containing doai, and said benzene...
514210, 5142262, 514359, 514376, 514460, 514471, 514569, 514577, 514724, 514776, A01N 5100
Patent
active
058497277
ABSTRACT:
This invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic or bioactive agents. The methods and composition of the invention can be used with several therapeutic or bioactive agents and can achieve site-specific delivery of a therapeutic or biologically-active substance. This can allow for lower doses and for improved efficacy with drugs, particularly agents such as oligonucleotides which are plagued with problems in achieving therapeutic levels at targeted sites.
REFERENCES:
patent: 4572203 (1986-02-01), Feinstein
patent: 4634586 (1987-01-01), Goodwin et al.
patent: 4718433 (1988-01-01), Feinstein
patent: 4774958 (1988-10-01), Feinstein
patent: 4844882 (1989-07-01), Widder et al.
patent: 4957656 (1990-09-01), Cerny et al.
patent: 5040537 (1991-08-01), Katakura
patent: 5107842 (1992-04-01), Levene et al.
patent: 5255683 (1993-10-01), Monaghan
patent: 5304325 (1994-04-01), Kaufman et al.
patent: 5310540 (1994-05-01), Giddey et al.
patent: 5315997 (1994-05-01), Widder et al.
patent: 5315998 (1994-05-01), Tachibana et al.
patent: 5385147 (1995-01-01), Anderson et al.
patent: 5385725 (1995-01-01), Lin et al.
patent: 5393524 (1995-02-01), Quay
patent: 5401493 (1995-03-01), Lohrmann et al.
patent: 5409688 (1995-04-01), Quay
patent: 5410516 (1995-04-01), Uhlendorf et al.
patent: 5413774 (1995-05-01), Schneider et al.
patent: 5439686 (1995-08-01), Desai et al.
patent: 5445813 (1995-08-01), Schneider et al.
patent: 5512268 (1996-04-01), Grinstaff et al.
patent: 5540909 (1996-07-01), Schutt
patent: 5542935 (1996-08-01), Unger et al.
patent: 5552133 (1996-09-01), Lambert et al.
patent: 5558853 (1996-09-01), Quay
patent: 5560364 (1996-10-01), Porter
patent: 5567415 (1996-10-01), Porter
patent: 5580859 (1996-12-01), Felgner et al.
Porter, et al., "Interaction of Diagnostic Ultrasound with Synthetic Oligonucleotide-Labeled Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles", J Ultrasound Med, 15:577-584 (1996).
Orkin, et al., Dec. 1995, Report and Recommendations of the Panet to Assess the NIH Investment in Research on Gene Therapy.
Gura, T, 1995, Science, vol. 270, pp. 575-577.
Bleeker, H., "On the Application of Ultrasonic Contrast Agents for Blood Flowmetry and Assessment of Cardiac Perfusion", Ultrasound Med, 9:461-471 (1990).
Putterman, S., "Sonoluminescene: Sound into Light", Feb. 1995, Scientific American, 46-51.
Porter, T., "Myocardial Contrast Echocardiography for the Assessment of Coronary Blood Flow Reserve: Validation in Humans", JACC, 21(2) 349-355 (1993).
Xie, F., "Acute Myocardial Ischemia and Reperfusion can be Visually Identified Non-invasively with Intravenous Perfluoropropane-Enhanced Sonicated Dextrose Albumin Ultrasound Contrast", Abstract From the 67th Scientific Sessions Dallas Convention Center, Dallas TX, Nov. 14-17, 1994 90(2) Part 2, Oct. 1994 (abstract).
Porter, T., "Echocardiographic Detection of Residual Coronary Flow Abnormalities and Stenosis Severity After Coronary Reperfusion Using Intravenous Perfluoropropane-enhanced Sonicated Dextrose Albumin", J. Am. Col. of Card., special issue, Feb. 1995 (abstract).
Kricsfeld, A., "Detection of Regional Perfusion Abnormalities During Adenoosine Stress Echocardiography Using Intravenous Perfluoropropane-enhanced Sonicated Dextrose Albumin", J. Am. Col. of Card., special issue, Feb. 1995 (abstract).
Porter, T., "Multifold Sonicated Dilutions of Albumin With Fifty Percent Dextrose Improve Left Ventricular Contrast Videointensity After Intravenous Injection in Human Beings", J. Am. Soc. Echocard., 7(5) 465-471 (1994).
Xie, F., "Perfluoropropane Enhanced Sonicated Dextrose Albumin Produces Visually Apparent Consistent Myocardial Opecification with Physiologic Washout and Minimal Homodynamic Changes Following. . . Injection", Abstract From the 67th Scientific Sessions Dallas Convention Center, Dallas TX, Nov. 14-17, 1994 90(4) Part 2, Oct. 1994 (abstract).
Porter, T., "Visually Discernible Myocardial Echocardiographic Contrast After Intravenous Injection of Sonicated Dextrose Albumin Microbubbles Containing Molecular Weight, Less Soluble Gases", J. Am. Col. of Card., 25(2) 509-515 (1995).
Porter, T., "Noninvasive Indentification of Acute Myocardial Ischemia and Reperfusion with Contrast Ultrasound Using Intravenous Perfluoropropane-Exposed Sonicated Dextrose Albumin", J. Am. Col. of Card., 26(1) 33-40 (1995).
Anderson editorial "Gene Therapy for Genetic Diseases", Human Gene Therapy, 5:281-282 (1994).
Challita, P., "Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo", Proc. Natl. Acad. Sci. USA, 91, 2567-2571.
Jaroff, "Keys to the Kingdom", Time, 148(14) 24-29, Fall 1996.
Porter, "Transient Myocardial Contrast After Initial Exposure to Diagnostic Ultrasound Pressures With Minute Doses of Intravenously Injected Microbubbles; Demonstration and Potential Mechanisms", Circulation, 92(9):2391-2395 (1995).
Coghlan, "Gene dream fades away", New Scientist, 148:14-15 (1995).
Brown, "New Media, Researchers" Oversold Gene Therapy, Advisory Panel Says, The Washington Post, p. A22 (1995).
Marshall, "Gene Therapy's Growing Pains", Science, 269:1050-1055 (1995).
Porter, "The mechanism and clinical implication of improved left ventricular videointensity following intravenous injection of multi-fold dilutions of albumin with dextrose", International J. of Card. Imag., 11:117-125 (1995).
Srinivasan, Shashi Kumar "Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin", Antisense Research and Development 5:131-139 (1995).
Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring, Third Edition (1992), Applied Therapeutics, Inc., Vancouver, WA.
Iversen Patrick L.
Porter Thomas R.
Board of Regents of the University of Nebraska
Ketter James
Yucel Irem
LandOfFree
Compositions and methods for altering the biodistribution of bio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for altering the biodistribution of bio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for altering the biodistribution of bio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1458040